NASDAQ NMS - GLOBAL MARKET · ALNY

+4.61% · +$10.10 · Vol 2.7M

After hours · updated 16:24:44 ET

Alnylam Pharmaceuticals Inc

Biotechnology

$229.10

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factors

Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET · ALNY

Methodology

ALNY

Alnylam Pharmaceuticals Inc

Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET

50/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

50/ 100

Veridion Score

NEUTRAL · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is ALNY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move ALNY next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 4
Score
Score moved -20
70/BUY BIAS -> 50/NEUTRAL
Veridion score historySource
May 12
CongressChecking access
Jefferson Shreve sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 29
CongressChecking access
Josh Gottheimer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 11
CongressChecking access
Josh Gottheimer purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 11
CongressChecking access
Josh Gottheimer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 6
CongressChecking access
Daniel Goldman purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 31
CongressChecking access
Daniel Goldman sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 4
CongressChecking access
Ro Khanna exchange disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Sep 28
CongressChecking access
Josh Gottheimer purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Alnylam Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS

Listed since

2004

Employees

Country

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$221.74

Day high

$229.65

Day low

$221.50

Previous close

$219.00

52W high

$491.22

-53.36% from high

52W low

$205.48

8% of range

Market cap

$29.3B

P/E

36.48×

EPS

$2.40

Beta

-0.18

Shares out

133.8M

Volume

2.7M

1.34× rel vol

Avg volume

VWAP

$227.25

Price history computed in-house

-20.07%

-26.81%

-22.58%

-45.31%

YTD

-42.39%

SMA 50 $283.56 · below

SMA 200 $345.53 · below

52W position 8%

ALNY overview

Veridion Score

6 of 6 factors measured

Congress receipts

Jefferson Shreve · Sale

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around ALNY.Congress disclosuresOpen receipt and filing context for ALNY.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

ALNY insider activity

Alnylam Pharmaceuticals Inc

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

No value-bearing Form 4 rows

The current Form 4 feed did not return value-bearing open-market rows for ALNY.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in ALNY

Congress tracker Open ticker disclosure ledger →

Jefferson ShreveSell

ALNY · Transaction May 12, 2025 · Filed Jun 22, 2025 · $15,001 to $50,000

Official filing ↗

Josh GottheimerSelljoint

Alnylam Pharmaceuticals, Inc. - Common Stock · Transaction Jan 29, 2024 · Filed Feb 15, 2024 · $1,001 to $15,000

Official filing ↗

Josh GottheimerBuyjoint

Alnylam Pharmaceuticals, Inc. - Common Stock · Transaction Jan 11, 2024 · Filed Feb 15, 2024 · $1,001 to $15,000

Official filing ↗

Josh GottheimerSelljoint

Alnylam Pharmaceuticals, Inc. · Transaction Dec 11, 2023 · Filed Jan 7, 2024 · $1,001 to $15,000

Official filing ↗

Daniel GoldmanBuy

ALNY · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $15,001 to $50,000

Official filing ↗

Federal contracts

ALNY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for ALNY in this window.

Lobbying spend

ALNY lobbying filings, year to date.

Registered lobbying filings matched to Alnylam Pharmaceuticals Inc.

$1.4M

Refresh interval: 12hSource: LDA disclosure filings

Medicare/MedicaidPharmacy Medicare/Medicaid Trade (domestic/foreign)Medicare/Medicaid Trade (domestic/foreign) Pharmacy

Filing

$450.0K

ALNYLAM PHARMACEUTICALS INC.

ALNYLAM PHARMACEUTICALS, INC.

Jul 20, 2026

Filing

$430.0K

ALNYLAM PHARMACEUTICALS INC.

ALNYLAM PHARMACEUTICALS, INC.

Apr 20, 2026

Filing

$390.0K

ALNYLAM PHARMACEUTICALS INC.

ALNYLAM PHARMACEUTICALS, INC.

Jan 20, 2026

Analyst ratings

Sovereign unlock shows live analyst consensus for ALNY.

Options

Sovereign unlock shows live options positioning for ALNY.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Why is ALNY moving today?

What can move ALNY next.

ALNY overview

Related filings and maps

ALNY insider activity

ALNY contract awards, year to date.

ALNY lobbying filings, year to date.

Cross-references from this score page.

What can move ALNY next.

ALNY insider activity

Cross-references from this score page.